Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reversibility of mitochondrial toxicity in HIV lipoatrophy

Trial Profile

Reversibility of mitochondrial toxicity in HIV lipoatrophy

Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Antiretrovirals; Stavudine; Zidovudine
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2010 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top